100 related articles for article (PubMed ID: 33032941)
1. Reply to "Keynote 48: Is it really for everyone?".
Burtness B; Ge J
Oral Oncol; 2021 Jan; 112():104983. PubMed ID: 33032941
[No Abstract] [Full Text] [Related]
2. Keynote 48: Is it really for everyone?
Schoenfeld JD; Fell G; Haddad RI; Trippa L
Oral Oncol; 2020 Jun; 105():104762. PubMed ID: 32381470
[No Abstract] [Full Text] [Related]
3. p16 status and choice of chemotherapy in the KEYNOTE-040 study - Authors' reply.
Cohen EEW; Soulières D; Swaby RF; Harrington KJ
Lancet; 2019 Oct; 394(10206):1323. PubMed ID: 31609223
[No Abstract] [Full Text] [Related]
4. Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH).
Tao Y; Aupérin A; Sun X; Sire C; Martin L; Coutte A; Lafond C; Miroir J; Liem X; Rolland F; Even C; Nguyen F; Saada E; Maillard A; Colin-Batailhou N; Thariat J; Guigay J; Bourhis J
Eur J Cancer; 2020 Dec; 141():21-29. PubMed ID: 33125944
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
Ferrarotto R; William WN; Tseng JE; Marur S; Shin DM; Murphy B; Cohen EEW; Thomas CY; Willey R; Cosaert J; Harun N; Jack Lee J; Wistuba IW; Haddad RI; Glisson BS
Oral Oncol; 2018 Jul; 82():83-90. PubMed ID: 29909907
[TBL] [Abstract][Full Text] [Related]
6. [Pembrolizumab is more effective and better tolerable than methotrexate, docetaxel, or cetuximab in recurrent or metastatic HNSCC (KEYNOTE-040)].
Hermann RM; Christiansen H
Strahlenther Onkol; 2019 Sep; 195(9):851-854. PubMed ID: 31250051
[No Abstract] [Full Text] [Related]
7. Further clinical interpretation and implications of KEYNOTE-048 findings.
Szturz P; Vermorken JB
Lancet; 2020 Aug; 396(10248):379. PubMed ID: 32771103
[No Abstract] [Full Text] [Related]
8. Further clinical interpretation and implications of KEYNOTE-048 findings.
McCaw ZR; Ludmir EB; Kim DH; Wei LJ
Lancet; 2020 Aug; 396(10248):378-379. PubMed ID: 32771102
[No Abstract] [Full Text] [Related]
9. Further clinical interpretation and implications of KEYNOTE-048 findings.
Revannasiddaiah S; Devadas SK; Maka VV; Kilara N
Lancet; 2020 Aug; 396(10248):378. PubMed ID: 32771101
[No Abstract] [Full Text] [Related]
10. Evaluation of Cetuximab in combination with radiotherapy or chemotherapy against advanced squamous cell carcinoma of the head and neck.
Li JZ; Zheng JW; Zhang ZY
Shanghai Kou Qiang Yi Xue; 2008 Feb; 17(1):1-5. PubMed ID: 18360658
[TBL] [Abstract][Full Text] [Related]
11. p16 status and choice of chemotherapy in the KEYNOTE-040 study.
Bins S; Mathijssen RHJ
Lancet; 2019 Oct; 394(10206):1322-1323. PubMed ID: 31609222
[No Abstract] [Full Text] [Related]
12. p16 status and choice of chemotherapy in the KEYNOTE-040 study.
Wei W; Ji M; Wu CP; Yang X
Lancet; 2019 Oct; 394(10206):1321-1322. PubMed ID: 31609221
[No Abstract] [Full Text] [Related]
13. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Cohen EEW; Soulières D; Le Tourneau C; Dinis J; Licitra L; Ahn MJ; Soria A; Machiels JP; Mach N; Mehra R; Burtness B; Zhang P; Cheng J; Swaby RF; Harrington KJ;
Lancet; 2019 Jan; 393(10167):156-167. PubMed ID: 30509740
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab vs the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
Lang Y; Dong D; Wu B
Clin Drug Investig; 2020 Dec; 40(12):1137-1146. PubMed ID: 33095408
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab-Induced Microscopic Colitis.
Ahmed M; Francis G
Am J Gastroenterol; 2018 Apr; 113(4):629-630. PubMed ID: 29610496
[No Abstract] [Full Text] [Related]
16. Cetuximab in the treatment of squamous cell carcinoma of the head and neck.
Specenier P; Vermorken JB
Expert Rev Anticancer Ther; 2011 Apr; 11(4):511-24. PubMed ID: 21504318
[TBL] [Abstract][Full Text] [Related]
17. Grading system and management guidelines for dermatitis induced by head and neck radiotherapy plus cetuximab: clinical validation required.
Langendijk JA; Oosting SF
Ann Oncol; 2011 Oct; 22(10):2157-9. PubMed ID: 21878428
[No Abstract] [Full Text] [Related]
18. Advanced Squamous Cell Carcinoma of the Head and Neck: The Current Role of Cetuximab.
Granados-García M; Aguilar-Ponce JL; Maldonado-Magos F; De la Garza-Salazar JG
ORL J Otorhinolaryngol Relat Spec; 2016; 78(6):320-333. PubMed ID: 28125819
[TBL] [Abstract][Full Text] [Related]
19. Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines.
De Pauw I; Wouters A; Van den Bossche J; Deschoolmeester V; Baysal H; Pauwels P; Peeters M; Vermorken JB; Lardon F
Cancer Biother Radiopharm; 2017 Sep; 32(7):229-238. PubMed ID: 28910149
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions.
Kao HF; Lou PJ
Head Neck; 2019 Oct; 41 Suppl 1():4-18. PubMed ID: 31573752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
